KYPROLIS® (carfilzomib) is indicated in combination with dexamethasone, or with lenalidomide
plus dexamethasone, or with daratumumab plus dexamethasone, or with daratumumab plus
hyaluronidase-fihj plus dexamethasone, or with isatuximab plus dexamethasone for the treatment
of adult patients with relapsed or refractory multiple myeloma who have received one to three lines
of therapy.
KYPROLIS® is indicated as a single agent for the treatment of
patients with relapsed or refractory multiple myeloma who have received one or more lines
of therapy.
